The incidence of treatment-related mortality associated with TAXOTERE therapy is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive TAXOTERE as a single agent at a dose of 100 mg/m2 [see Warnings and Precautions].
TAXOTERE should generally not be given to patients with bilirubin > upper limit of normal (ULN), or to patients with SGOT and/or SGPT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia grade 4 but did not have an increased incidence of toxic death. Bilirubin, SGOT or SGPT, and alkaline phosphatase values should be obtained prior to each cycle of TAXOTERE therapy and reviewed by the treating physician.
TAXOTERE therapy should not be given to patients with neutrophil counts of <1500 cells/mm3. In order to monitor the occurrence of neutropenia, which may be severe and result in infection, frequent blood cell counts should be performed on all patients receiving TAXOTERE.
Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely fatal anaphylaxis, have been reported in patients who received the recommended 3-day dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the TAXOTERE infusion and administration of appropriate therapy [see Warnings and Precautions]. TAXOTERE must not be given to patients who have a history of severe hypersensitivity reactions to TAXOTERE or to other drugs formulated with polysorbate 80 [see Contraindications (4) ].
Severe fluid retention occurred in 6.5% (6/92) of patients despite use of a 3-day dexamethasone premedication regimen. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [see Warnings and Precautions].
Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants. The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-
-butyl ester, 13-ester with 5(beta)-20-epoxy-1,2(alpha),4,7(beta),10(beta),13(alpha)-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate.
TAXOTERE is indicated for the following:
Breast Cancer: TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
Non-Small Cell Lung Cancer: TAXOTERE as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
TAXOTERE in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
Prostate Cancer: TAXOTERE in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.
Media Articles Related to Taxotere (Docetaxel)
Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer
Source: Lung Cancer News From Medical News Today [2016.10.11]
The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy...
MEK inhibition in KRAS-mutant non-small-cell lung cancer (NSCLC) did not improve survival
Source: Lung Cancer News From Medical News Today [2016.10.12]
MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to data...
Published Studies Related to Taxotere (Docetaxel)
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or
placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG
Oncology/Gynecologic Oncology Group study. 
progression-free survival (PFS) in uLMS... CONCLUSION: The addition of bevacizumab to gemcitabine-docetaxel for first-line
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia
with human epidermal growth factor receptor 2-positive metastatic breast cancer:
results from the phase III trial CLEOPATRA. 
metastatic breast cancer... CONCLUSION: Despite a higher proportion of docetaxel dose reductions in patients
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without
selumetinib in wild-type BRAF advanced melanoma. 
wild-type BRAF advanced melanoma... CONCLUSIONS: The combination of docetaxel with selumetinib showed no significant
[Efficacy and safety of rh-endostatin combined with docetaxel in second-line or
intolerant toxicity for first-line treatment in patients with advanced non-small
cell lung cancer]. [Article in Chinese] 
chemotherapy... CONCLUSIONS: Endostar may prolong TTP in patients with advanced NSCLC benefited
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced
castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. 
bone metastases... INTERPRETATION: Atrasentan, when added to docetaxel, does not improve overall
Clinical Trials Related to Taxotere (Docetaxel)
Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer [Completed]
The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of
docetaxel between two docetaxel products in patients with advanced solid cancer.
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients [Recruiting]
The purpose of this study is to learn if the biomarker information obtained (learned or
received) from the earlier studies can tell us whether or not Taxotere and/or
Adriamycin/Cytoxan can cause tumors to become smaller.
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer [Recruiting]
Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes
induced by docetaxel in HRPC patients
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer [Terminated]
We, the investigators at Baylor Breast Care Cancer, are doing this study to learn how well
Taxotere makes tumors become smaller. We are also doing this study to find out how well
Taxotere treats the type of breast cancer that some patients have. We are asking patients to
take part in this study because they have locally advanced breast cancer. Women with this
breast cancer will usually receive chemotherapy medicines to reduce or shrink the cancer
before surgery to take out the cancer. If patients choose to take part in this study, they
will receive Taxotere and the combination of cyclophosphamide and doxorubicin. These
medicines are part of the standard good medical care for this type of breast cancer. They
are approved for the treatment of this problem. To help us learn how the patients' cancer
responds to these medicines, we will take a small tissue sample (biopsy) of the patients'
breast cancer before beginning treatment, one day after the first dose of treatment, once
each week for the first three weeks of treatment, and when surgery is done as part of
treatment for their cancer. These samples will be collected also to look at the biology of
the patients' cancer. We will also use a new method called cDNA array technology, which lets
us look at thousands of genes (coding information inside the cancer cell) at once. By
looking at different genes in the breast cancer, we may learn important information about
which cancers will respond to a chemotherapy medicine. We hope to learn if there are
different gene patterns in patients whose tumors shrink or do not shrink with this
chemotherapy medicine. This information may help us, in the future, to choose the right
medicines for women with breast cancer so that they have the highest chance of their cancer
shrinking with chemotherapy medicine. We cannot and do not know if patients will benefit if
they take part in this study.
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (TaxotereŽ) for Subjects With Advanced Cancer Tumors [Terminated]
The purpose of this study is to test the combination of an experimental drug known as
MGCD0103 given along with an FDA-approved drug called docetaxel. This is a Phase 1 study
that will look at different doses of MGCD0103 given along with docetaxel in order to better
understand the effects (positive and negative) of this combination on the subject's body and
The study would like to find the following information:
- How long MGCD0103 and docetaxel stay in the subject's body;
- What effects, good and/or bad, MGCD0103 and docetaxel have on the subject and on
his/her cancer; and
- If the genetic and chemical make-up of the subject's blood cells and tumor cells play a
role in how you respond or do not respond to MGCD0103 and docetaxel.
Reports of Suspected Taxotere (Docetaxel) Side Effects
Interstitial Lung Disease (58),
Febrile Neutropenia (36),
Hypotension (30), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Taxotere has an overall score of 8. The effectiveness score is 10 and the side effect score is 4. The scores are on ten point scale: 10 - best, 1 - worst.
Taxotere review by 48 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || Cancer|
|Dosage & duration:|| || not sure standard for breast cancer (dosage frequency: 3 weeks) for the period of 6 cycles|
|Other conditions:|| || netropenia|
|Other drugs taken:|| || tamoxien|
|Benefits:|| || Longer life expectancy but wish I had know that my ovaries could be turned off before I started the drug then switched on again afterwards. As it is I went into a early menopuse with very, very, severe side effects.Please get your Doctor to talk about ALL the possible side effects of menopause, including sexual.|
|Side effects:|| || netropenia, stort of breath , muscle weakness, nausea, hair loss, menopuse, unable to find any peace of mind. Would reccomend eating bucket fulls of fruit.|
|Comments:|| || 1 injection every 3 weeks. Then a reduction in the dose by 25 percente after the 4 th week due to netropenia.|
Page last updated: 2016-10-12